0
0
7/17/23 at 7:58pm
Organization
Pharmacytimes.com
31 words
0
Comments
The approval marks the first monoclonal antibody approved to protect all infants through their first respiratory syncytial virus season.
You are the first to view
https://www.pharmacytimes.com/view/fda-approves-nirsevimab-alip-to-prevent-rsv-in-infants-toddlers
Create an account
or login to join the discussion